dermatology

News

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

Patients

Chronic skin conditions, particularly CHE, remain some of the most underestimated, yet pervasive, challenges affecting people across Europe.

News

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.